Posted on May 21st, 2012 by Health News
The histone de-acetylase (HDAC) inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central’s open access journal Breast Cancer Research.
No Comments »
Filed under: Pharmacy News
Posted on May 20th, 2012 by Health News
Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that an abstract reporting new data from the BiovaxID Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with the significance of these results to be presented by the NCI at the 2012 [...]
No Comments »
Filed under: Pharmacy News
Posted on May 19th, 2012 by Health News
ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of their investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer.
No Comments »
Filed under: Pharmacy News
Posted on May 19th, 2012 by Health News
A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
No Comments »
Filed under: Pharmacy News
Posted on May 19th, 2012 by Health News
Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference “2012 ASCO Annual Meeting” to be held in Chicago (USA) on 1-5 June 2012.
No Comments »
Filed under: Pharmacy News
Posted on May 18th, 2012 by Health News
For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery. A large randomized clinical trial published in 2003 demonstrated a survival benefit for neoadjuvant, or pre-surgical, MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) using a [...]
No Comments »
Filed under: Pharmacy News
Posted on May 18th, 2012 by Health News
Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of advanced ovarian cancer.
No Comments »
Filed under: Pharmacy News
Posted on May 18th, 2012 by Health News
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that additional data from a Phase 1 safety and proof-of-concept study evaluating lead candidate, galeterone, in patients with castration-resistant prostate cancer (CRPC) will be highlighted in a poster presentation titled, “Phase I clinical trial of galeterone, a multifunctional anti-androgen [...]
No Comments »
Filed under: Pharmacy News
Posted on May 18th, 2012 by Health News
Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid-, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute.
No Comments »
Filed under: Pharmacy News
Posted on May 18th, 2012 by Health News
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
No Comments »
Filed under: Pharmacy News